PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 80: Articles 39501-40000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Honduras: fertility and an evaluation of family planning programs.
  2. Hormonal contraception. [Contracezione ormonale.]
  3. Hormonal contraception. [La contraception hormonale.]
  4. Hormonal contraception. Clinical Experience, gained up to now, and present-day problems. [Hormonalna antykoncepcja. Dotychczasowe doswiadczenia kliniczne, aktualne problemy.]
  5. Hormonal contraceptives and lipid metabolism. [Anticonceptionnels hormonaux et metabolsime des lipides.]
  6. Hormonal contraceptives. [Anticonceptivos hormonales.]
  7. The hospital and its function in a family planning program.
  8. Hungarian fertility and family planning studies.
  9. Hungary. (Family planning.)
  10. Hypertension arterielle severe stenose d'une artere renale, trouble de la glycoregulation et pilule contraceptive. (Severe arterial hypertension, stenosis of a renal artery, poor glucoregulation and the contraceptive pill.)
  11. Immediate postpartum oral contraception.
  12. Immunological studies on human antithrombin 3. Influence of age, sex, and use of oral contraceptives on serum concentration.
  13. The impact of contraceptive culture.
  14. Impact of the post-partum family-planning program in Thailand.
  15. Interim federal specification condom, rubber contraceptive (with amendment)
  16. Internal external locus of control and the practice of birth control.
  17. International convention on planned parenthood in Budapest from 15 to 17 September 1969. [Mezinarodni konference o planovanem rodicovstvi Budapest 15.-17.9.1969.]
  18. An internist's observations of patients on long-term contraception.
  19. Intra-uterine contraception.
  20. Intra-uterine contraceptive device with ectopic gestation.
  21. The legislative status of sex and birth control education in the United States.
  22. The link of socio-economic factors with family planning. [Svyaz sotsialno-ekonomicheskikh faktorov s planirovaniem semi.]
  23. The local geography of birth control.
  24. Long-acting injectable contraception with medroxyprogesterone acetate.
  25. Long-acting injectable steroids as contraceptives: a comparative study of two agents.
  26. Long-term effect of an intrauterine contraceptive device on genital organs of rhesus monkeys: a 4 1/2 year study.
  27. Long-term toxicologic and tumorigenesis studies on an oral contraceptive agent in albino rats.
  28. Louisiana's quiet revolution in family planning.
  29. Low dosage mesgestrol acetate application as contraceptive.
  30. Low-dose progestagens as contraceptive agents.
  31. Low-oestrogen oral contraceptives.
  32. Lynestrenol 1 mg.-mestranol 0.1 mg: a new low dose oral contraceptive: a clinical study.
  33. Magnesium and citrate during the menstrual cycle: effect of an oral contraceptive on serum magnesium.
  34. Major vascular accidents during treatment with oral contraceptives and retrospective discovery of an idiopathic hyperlipidemia: a report of 9 cases. [Accidents vasculaires majeurs en cours de traitement contraceptif oral, et decouverte retrospective d'une hyperlipidemie idiopathique: a propos de 9 observations.]
  35. Malabsorption of folate polyglutamates associated with oral contraceptive therapy.
  36. Malaysia National Family Planning Programme, its progress and achievements.
  37. The male contraceptive: a bitter pill?
  38. Male sterilisation: an ultimate in family planning.
  39. Male use of contraception and attitudes towards abortion, Santiago, Chile, 1968.
  40. Manufacturers cut promising contraceptive research, saying FDA regulations requiring animal toxicity studies are too time-consuming, expensive.
  41. Marketing the innovation of contraceptives to post-partum patients.
  42. Marxism and birth control.
  43. Maternal and child health problems encountered in a family planning.
  44. Maternal nutrition and family planning in the Americas. Report of a group meeting.
  45. Maternal nutrition and family planning in the Americas: report of a PAHO technical group meeting Washington, D.C., October 20-24, 1969.
  46. Maternal nutrition and family planning.
  47. The Mauritius Family Planning Programme.
  48. A means of more physiological hormonal contraception. [Ein Weg zu einer mehr physiologischen hormonalen Kontrazeption.]
  49. Measurement of accomplishment: the evaluation of family planning efforts.
  50. The measurement of the economic benefits from family planning projects and programs.
  51. Mechanical methods of contraception.
  52. Mechanism of action of hormonal contraceptives. [Mecanismo de accion de los anticonceptivos hormonales.]
  53. Mechanism of action of intrauterine contraceptives in women.
  54. Mechanism of action of oral contraceptives. [Mecanismo de accion de los anticonceptivos orales.]
  55. Mechanism of the action of intrauterine contraceptive devices. [K voprosu o mekhanizme kontraktseptivnovo effekta vnutrimatochnykh sredstv.]
  56. Mechanisms of action of intra-uterine contraceptive devices in women and other mammals.
  57. Medical and biological aspects of contraception. [Aspetti medici e biologici della contraccezione.]
  58. Medical aspects of oral contraceptives.
  59. Medical correlates of termination of use of intrauterine contraceptive devices in Taichung.
  60. Medical education and family planning---III. What departments of preventive and social medicine are doing in India.
  61. Medical indications for oral contraceptives. [Les indications medicales des contraceptifs oraux.]
  62. Meeting of Experts on Education and Family Planning, Paris, 20-24 April 1970. Final report.
  63. Megaloblastic anemia precipitated by the use of oral contraceptive: a case report.
  64. Menstrual blood loss during oral contraceptive therapy and in IUD users.
  65. Menstrual dysfunction following use of oral contraceptives.
  66. Mental health and family planning.
  67. Mesenteric venous thrombosis associated with oral contraceptives.
  68. Metabolic effects of oral contraceptives.
  69. Metabolic effects of oral contraceptives. (Letter to the editor)
  70. Metabolic effects of steroid contraceptives.
  71. Metabolism of progestogen administered in oral contraceptives.
  72. A method for estimating future caseloads of family planning programs.
  73. Methodological problems in psychosociological research in family planning.
  74. Microdose intrauterine progestagen associated with intrauterine contraceptive devices.
  75. Microglandula hyperplasia of endocervical glands as a consequence of the use of oral contraceptives. [Mikroglandularna hiperplazija endocervikalnih zlijezda kao posljedica uzimanja oralnih kontraceptiva.]
  76. Microscopic and clinical study of the inhibition of sperm fertility by 799R. Contraceptive trials--114 cases. [Etude microscopique et clinique de l'inhibition du pouvoir fecondant spermatique par le 799 R. Contraceptive trials--114 cases.]
  77. Midwives recognize importance of contraception.
  78. Migraines and oral contraceptives. [Migraines et contraceptifs oraux.]
  79. Modern contraception and venereal disease.
  80. Modification of certain metabolic indicators under the influence of an oral contraceptive. [Changement de certains indices du metabolisme sous l'effet d'un produit anticonceptionnel administre par voie orale.]
  81. Morocco: family planning an an attitude survey in the urban areas.
  82. Morocco: family planning attitudes, knowledge, and practice in the Sais Plain.
  83. Morocco: family planning knowledge, attitudes, and practice in the rural areas.
  84. Morocco: family planning knowledge, attitudes, and practices in the rural areas.
  85. Morphologic changes in the uterus associated with steroid contraceptives and intrauterine contraceptive devices.
  86. Morphological effects of intrauterine contraceptive devices.
  87. Morphological findings in endometrium, decidua, and chorion following a long-term application of an intrauterine contraceptive device. [Morfologicke nalezy na endometriu, decidui a choriu po dlhsie trvajucom pouziti intrauterinneho antikoncepcneho telieska.]
  88. Morphophysiology of the ovary of women treated with different steroids used as contraceptives. [Morfofisiologia del ovario de mujeres tratadas con diferentes esteroides usados como contraceptivos.]
  89. Mortality from coronary occlusion in young women with reference to oral contraceptives as a possible etiological factor. [Mortaliteten af koronarpkklusion hos yngre kvinder med henblik pa p-pillen som en mulig aetiologisk faktor.]
  90. Motivation in family planning.
  91. Mysore among the southern states in the Family Planning Programme.
  92. The National Family Planning Programme in Pakistan.
  93. The National Family Planning Programme in Trinidad and Tobago: 1968-1972.
  94. National family-planning programs: where we stand.
  95. National Intra-uterine Contraception Report.
  96. Nature's own method of contraception.
  97. The Nelson hearings on oral contraceptives-testimony: Part 1.
  98. Net delay of next conception by contraception: a highly simplified case.
  99. Neuro-ophthalmological complications in the wake of oral contraceptives. [Powiklania neuro-okulistyczne w nastepstwie stosowania doustnych srodkow antykoncepcujnych.]
  100. Neurologic complications after oral contraceptives. [Powiklania neurologiczne po stosocwaniu doustnych srodkow antykoncepcyjnych.]
  101. Neurologic pathology of oral contraceptives. [Neurologische Pathologie der hormonalen Antikonzeption.]
  102. New feminism: potent force in birth-control policy.
  103. New methodology and new technology in family planning organization.
  104. New national program of family planning in the United States. [El nuero programma nacional de planeacion familiar en los Estados Unidos.]
  105. A new oral contraceptive with a 7 plus 15 sequential formulation.
  106. A new postcoital oral contraceptive.
  107. New report on oral contraceptives of the Advisory Committee to the Food and Drug Administration. Reply to Dr. Goldzieher's comment on the new report.
  108. New report on oral contraceptives of the Advisory Committee to the Food and Drug Administration: a comment on the new report.
  109. A new type of oral contraceptive.
  110. New York City's in-hospital family planning program.
  111. News release. (Oral contraceptives)
  112. Ninth survey - 1967: "affluent life" - disseminating family planning.
  113. Nonmonetary commodity incentives in family planning programmes: a preliminary trial.
  114. Norgestrel-ethinyl estradiol - an oral contraceptive: a clinical study of 725 patients.
  115. Normal sequential treatment. Experiences with an 11:10 variant of the sequential method for contraception and for medical indications. [Zyklusgerechte Zweiphasen-Behandlung. Erfahrungen mit einer 11:10 Variante der Zweiphasen-Methode zur Konzeptionskontrolle und fur medizinische Indikationen.]
  116. Notes on current drugs: a report from the Australian Drug Evaluation Committee: oral contraceptives and thromboembolic disease.
  117. Notes on current drugs: oral contraceptives and thromboembolic disease.
  118. Nurse's role in family planning at a municipal hospital.
  119. Oestrogen content of oral contraceptives and thromboembolism.
  120. Oestrogen levels in oral contraceptives.
  121. Older than history. (Birth control)
  122. On some psychiatric complications of oral contraception. [De quelques incidences psychiatriques de la contraception orale.]
  123. On the family planning program in India with special reference to Gandhigram.
  124. On the history of hormonal contraception: I. Ludwig Haberlandt (1885-1932) and his concept of "hormonal sterilization".
  125. On vaginal moniliasis during pregnancy and during intake of oral contraceptives. [Uber den Soorbefall der Scheide wahrend der Schwangerschaft und unter Einnahme oraler Kontrazeptiva.]
  126. Once a month oral contraceptive: Quinestrol and Quingestanol.
  127. Once-monthly injection as a contraceptive. [Monatliche Einmalinjektion als Kontrazeptivum.]
  128. Opinion study regarding the establishment of a family planning clinic. [Estudio de opinion ante la instalacion de una clinica de planificacion familiar.]
  129. Opposition to family planning in Latin America: the non-Marxist left.
  130. Oral contraception among special clinic patients with particular reference to the diagnosis of gonorrhoea.
  131. Oral contraception and hypertension once more. [Oral antikonsepsjon og hypertensjon - enda en gang.]
  132. The oral contraception controversy.
  133. Oral contraception.
  134. Oral Contraception: an application in family planning programme in Calcutta city.
  135. Oral contraceptive steroids: effects on various nutrient balances and body composition in adult female rats.
  136. Oral contraceptive survey.
  137. Oral contraceptives -- prescribe or proscribe?
  138. Oral contraceptives and acute surgery. [Orale kontraceptiva og akut kirurgi.]
  139. Oral contraceptives and alopecia. [Anovulatorios y alopecia.]
  140. Oral contraceptives and amino acid utilization.
  141. Oral contraceptives and blood lipids.
  142. Oral contraceptives and blood pressure.
  143. Oral contraceptives and cervical neoplasia.
  144. Oral contraceptives and copper metabolism.
  145. Oral contraceptives and depression. (Letter to the editor)
  146. Oral contraceptives and female mortality trends.
  147. Oral contraceptives and gastrointestinal disorders.
  148. Oral contraceptives and glucose tolerance. (Letter)
  149. Oral contraceptives and glucose tolerance: a clinical study of three different oestrogen-progestogen combinations.
  150. Oral contraceptives and hypertension.
  151. Oral contraceptives and hypertension.
  152. Oral contraceptives and hypertension: the effect of guanethidine.
  153. Oral contraceptives and hypertensive disease: a cybernetic overview.
  154. Oral contraceptives and liver function.
  155. Oral contraceptives and low antithrombin-III activity.
  156. Oral contraceptives and low antithrombin-III activity.
  157. Oral contraceptives and low antithrombin-III concentration.
  158. Oral contraceptives and myocardial infarction.
  159. Oral contraceptives and neurologic complications. [Orale Kontrazeptiva und neurologische Komplikationen.]
  160. Oral contraceptives and premenstrual depression.
  161. Oral contraceptives and serum lipids.
  162. Oral contraceptives and serum-proteins.
  163. Oral contraceptives and the incidence of thrombosis. [Trombosefaren ved bruk av orale antikonsepsjonsmidler.]
  164. Oral contraceptives and their clinical evaluation.
  165. Oral contraceptives and thromboembolic disorders.
  166. Oral contraceptives and thromboembolism.
  167. Oral contraceptives and thrombosis. [Oral antikonsepsjon og trombose.]
  168. Oral contraceptives and thrombosis. Some coagulation and fibrinolysis changes. [Noen koagulasjons. Og fibrinolyseforandringer.]
  169. Oral contraceptives prescribed by the physician. [Anticonceptivos orales por indication medica.]
  170. Oral contraceptives, depression and aminoacid metabolism.
  171. Oral contraceptives.
  172. Oral contraceptives: a review of certain metabolic effects and an examination of the question of safety.
  173. Oral contraceptives: a status report.
  174. Oral contraceptives: current status of therapy.
  175. Oral contraceptives: depression and frigidity.
  176. The oral contraceptives: their composition, properties, selection and performance.
  177. Oral contraceptives: turmoil and aftermath.
  178. Ortho 1557-O: a new oral contraceptive.
  179. Orthopedics and oral administration of contraceptives.
  180. Other methods of birth control.
  181. Our experience with intrauterine contraception. [Notre experience de la contraception intra-uterine.]
  182. Ovarian changes during and after long term steroid contraceptive therapy.
  183. The ovaries during administration of contraceptive steroids. [Les ovaires au cours de l'administration des sterpides anticonceptionnels.]
  184. An overview of contraceptive methods applied at the time of coitus.
  185. An overview of family planning communication materials in radio.
  186. Overview of trends in family planning and abortion.
  187. Ovostat, a low-dose oral contraceptive. [Ovostat, contraceptif oral a faible dose.]
  188. Pakistan: plan for a radio communication campaign to raise the level of knowledge concerning family planning in Pakistan.
  189. Participation of low-income urban women in a public birth control program.
  190. A peep into family planning. Rev 2nd ed.
  191. The "perfect contraceptive" population.
  192. Perforation of bicornuate uterus by intrauterine contraceptive device.
  193. Permanent contraception: Sterilization general considerations.
  194. Peroral contraception, 8: changes in laboratory test results. [Peroral antikonception, 8: forandring av laboratorievarden.]
  195. Peroral contraception: 1. Drugs. [Peroral antikonception: 1. Preparat.]
  196. Peroral contraception: 2. Pharmacodynamics and clinical experiences. [Peroral antikonseption: 2. Verkningsmekanism och klinisk rutin.]
  197. Peroral contraception: 3. Clinical viewpoint. [Peroral antikonception: 3. Kliniska synpunkter.]
  198. Peroral contraception: 4. Pregnancies. [Peroral antikonception: 4. Gravidteter.]
  199. Peroral contraception: summary. [Peroral antikonception: sammanfattning.]
  200. Peroral contraception:5. Continual low dosage treatment. [Peroral antikonception:5. Kontinuerlig lagdosbehandling.]
  201. Perspectives on care programming and family planning.
  202. Pharmacologic approach to contraception.
  203. Pharmacology of contraceptive steroids. [Pharmacologie des steroides contraceptifs.]
  204. The Philippine family planning program: some suggestions for dealing with uncertainties.
  205. Phlebographic studies of the leg veins in the first half of pregnancy and during oral contraception.
  206. Physical check-ups in family planning.

     

  207. Physiologic and morphologic alterations effected by the contraceptive use of depo-medroxyprogesterone acetate.
  208. The pill -- safe? Clinical evaluation of oral contraceptives.
  209. The pill parallels the placenta: a method of teaching oral contraception.
  210. The pill scale--a technique for the measurement of attitudes toward oral contraception.
  211. Pilot study of a new low dose oral contraceptive in Ghana.
  212. Plan for integration of family planning with general health services.
  213. Planning and implementing a large-scale family planning program in Georgia.
  214. The planning of family planning. [Planung der Familenplanung.]
  215. The planning of the family.
  216. Planning, administration, and operation of family planning clinics.
  217. Plasma cortisol after one to sixty cycles of oral contraception.
  218. Plasma LH levels during oral contraceptive therapy.
  219. Plasma-proteins and oral contraceptives.
  220. Platelet adhesiveness in women using oral contraceptives.
  221. Platelet adhesiveness, aggregation and fibrinolysis after the oral administration of the contraceptive "Lyndiol."
  222. Poland. (Family planning.)
  223. Polyethylene intrauterine contraceptive device: endometrial changes following long-term use.
  224. Population policy: beyond family planning.
  225. Population, birth control and West Virginia.
  226. The possibilities of family planning in Africa. [Les possibilites de la planification familiale en Afrique.]
  227. A possible mechanism for hypertension induced by oral contraceptives: diminished feedback suppression of renin release.
  228. Post-acceptance experience and duration of use of contraception.
  229. Post-enumeration cum KAP survey: a report on the conduct of the combined census post-enumeration and family planning knowledge, attitude and practice survey, West Malaysia, 1970.
  230. Post-partum family-planning programs and their relation to the training of medical students and physicians.
  231. Postcoital contraception.
  232. Postcoital contraception.
  233. Postoperative thromboembolism and the use of oral contraceptives.
  234. Practice and motivation of contraception in Holland. [Praxis und Motivationen der Antikonzeption in Holland.]
  235. Prediction in family planning.
  236. Pregnancies and contraception.
  237. Pregnancies with intra-uterine contraceptive devices.
  238. Preliminary Report: A study of knowledge, attitude, and practice relative to family planning among indigenous women in Guam, 1969.
  239. Preliminary study on the views of the family planning health assistants on family planning and methods practised by them.
  240. Present methods and future possibilities (Contraception)
  241. Present situation in treatment with hormonal contraceptives. [La situazione attuale nel trattamento con contraccettivi ormonali.]
  242. The present state of family planning programs.
  243. Present status of injectable contraceptives: results of seven-years study.
  244. Prevention of lysis in human and rat ejaculate as a method of birth control.
  245. Principles of production and use of mass media for family planning programmes.
  246. The probability of conception after discontinuance of oral contraception: a note on "Oral contraception, coital frequency, and the time required to conceive," by Westoff, Bumpass, and Ryder.
  247. The problem of birth control.
  248. The problem of birth control: we need further research on many aspects of the problem. [Il problema del controllo delle nascite: occorre approfondire le ricerche su numerosi aspetti del problema.]
  249. Problems affecting the maternal and child health and family planning programs in Central America.
  250. Problems in interpretation and projection of fertility changes in a continuing program of population projections: with special reference to evaluation of goals and achievements of family planning programs.
  251. Problems of oral contraception. [Problemi di contraccezione orale.]
  252. Proceedings of the Conference on Psychosocial Factors in Transnational Family Planning Research.
  253. Proceedings of the Research Planning Conference for Transnational Studies in Family Planning, September 18-19, 1969, Hotel Gellert, Budapest, Hungary.
  254. Professional manpower in family planning: a study in Michigan.
  255. Program planning for family planning services.
  256. Progress in contraception. [Pokroky v antikoncepci.]
  257. Projected effects of family planning on the incidence of perinatal mortality in a lower-class nonwhite population.
  258. Prolonged amenorrhea following oral contraception.
  259. Promiscuity and contraception in a sample of patients attending a clinic for venereal diseases.
  260. Pros and cons of oral contraceptives.
  261. Protestant ministers' knowledge, attitude and practice about family planning, sex education and marriage.
  262. Psychoendocrine study of oral contraceptive agents.
  263. A psychological analysis of oral contraceptives and the intrauterine device.
  264. Psychological aspects of contraception.
  265. Psychological disturbance and oral contraceptives.
  266. Psychological sources of resistance to family planning.
  267. Psychology and population: behavioral research issues in fertility and family planning.
  268. Psychophysiologic changes accompanying oral contraceptive use.
  269. Psychosocial factors in transnational family planning research.
  270. Psychosocial studies in family planning behavior in central and eastern Europe: a preliminary report of a developing program.
  271. Public and private opinion on population and family planning.
  272. Public participation in a national family planning programme: Ceylon.
  273. Public participation in a national family planning programme: India.
  274. Pulmonary embolus, oral contraceptives, and a clinical search.
  275. Pyridoxine and oral contraceptives.
  276. Pyridoxine, estrogenic contraceptive steroids (ECS), and tryptophan metabolism.
  277. Questions and answers about the birth control pills.
  278. R 2323 - an original contraceptive compound. (Abstract only)
  279. Radiographic observations on the missed intra-uterine contraceptive device.
  280. Rate of plasma protein normalization after parturition and withdrawal of oral contraceptives.
  281. Raynaud-like clinical picture during treatment with an oral contraceptive. [Raynaudahnliches Krankheitsbild wahrend der Behandlung mit einem oralen Ovulationshemmer.]
  282. Reasons for practicing contraception.
  283. Recent trends in attitudes toward fertility control and in the practice of contraception in the United States.
  284. Recurrent polyneuropathy with pregnancy and oral contraceptives.
  285. Reduction of plasma tyrosine by oral contraceptives and oestrogens: a possible consequence of tyrosine aminotransferase induction.
  286. Regression of cerebral lesions after cessation of oral contraceptives.
  287. The relationship between attitudes and behavior: the case of family planning.
  288. Relationship of family planning to pediatrics and child health.
  289. Relative effectiveness (Contraceptive methods)
  290. Religion of Islam on family planning.
  291. Remarks on a case of temporary hemiparesis during treatment with oral contraceptives. [Considerazioni su un caso di emiparesi transitoria in corso di trattamento con contraccettivi orali.]
  292. The remote changes in the endometrial histology and the cervicovaginal cytology with the long acting hormonal contraceptive.
  293. Removal of barriers to family planning.
  294. A report from the Australian Drug Evaluation Committee: oral contraceptives and thromboembolic disease.
  295. Report of Near East South Asia Far East workshop on literacy population family planning and education (New Delhi and Lucknow, India, April-May 1970)
  296. Report of Near East/South Asia/Far East workshop on literacy/population/ family planning education.
  297. Report on the pilot study on Depo-Provera as a method of contraception in Kandnag Kerbau Family Planning Clinic and Queenstown Maternal and Child Health Clinic from February 15 1968 to February 14 1970.
  298. Report on the use of oral contraceptives in the Singapore National Program: a study of continuation rates of oral contraception based on 30 months experience.
  299. Report on topical investigation and analysis of intensive versus extensive use of resources where sterilization is the primary method of contraception.
  300. Report on topical investigation and analysis of nutritional supplements in family planning programs in India and Pakistan.
  301. Report on topical investigation and analysis of operational and performance statistics of family planning programs in Pakistan.
  302. Report on topical investigation and analysis of promoting family planning through health services.
  303. Requirements for the extension of maternity care and family planning through countries of the developing world.
  304. Research in reproductive biology and contraceptive technology: present status and needs for the future.
  305. Research report: family planning and conjugal roles in New York City poverty areas.
  306. The responsibility of the medical school in family planning.
  307. Results of clinical trials of Ovostat as a contraceptive and therapeutic agent. [Rezultati ot klinichnoto izpitvane na ovostata kato antikontseptsionno i terapevtichno sredstvo.]
  308. A review of the long-term effects of hormonal contraceptives.
  309. A review: establishing family planning services in Kenya.
  310. Richter's hernia resulting from displaced intrauterine contraceptive device.
  311. Risks of rhythm method of birth control.
  312. Risks, dangers, and efficacy of oral contraceptives.] [Statement.
  313. The role of family planning in prevention of pregnancy wastage.
  314. The role of foreign consultants in programmes of developing countries for nutrition, family planning, etc.: some general comments on nutrition and family planning.
  315. Role of para-medical personnel in the family-planning program in Pakistan.
  316. Role of pediatrician in family planning.
  317. Role of post-partum program in the national program of Singapore. In: Zatuchni, G.I., ed. Post-partum family planning: a report on the international program.
  318. The role of the hospital in the National family Planning Program, Trinidad and Tobago.
  319. The role of the pharmacist in family planning.
  320. Ryukyu Islands (Okinawa). (Family planning)
  321. Safety of oral contraception.
  322. Safety of oral contraceptives.
  323. Sagittal sinus thrombosis related to oral contraceptives: case report.
  324. Sale of Nirodh through commercial agencies in the villages surrounding regional family planning training centre, Hubli.
  325. Sample registration technique in evaluating family planning programme.
  326. Sarcoidosis in a patient on oral contraceptive therapy.
  327. Scarcity and family planning in Honduras.
  328. Science, birth control, and the Roman Catholic Church.
  329. The scientific basis of contraception.
  330. Second survey - 1952: Actual situation of birth control.
  331. Second trimester foetal death associated with an intrauterine contraceptive device.
  332. Selected aspects of the contraceptive practices of unmarried university students.
  333. Selective fecundability and contraceptive effectiveness.
  334. Selling birth control: the inception and early findings of Population Services, Inc.
  335. Sequential contraception: observations on new and "change-over" patients in a clinic population.
  336. Serum levels of nonesterified fatty acids and free amino acids under the effect of the oral contraceptive Ovosiston. [Der Serumspiegel unveresterter Fettsauren und freier Aminosauren unter Wirkung des Kontrazeptivum Ovosiston.]
  337. Serum lipids during oral contraceptive exposure.
  338. Seven years of family planning in Dharwar 1962-1969: a study of knowledge, attitude and practice of family planning.
  339. Seventh survey - 1963: How is family planning going on?
  340. Sexuality, contraception and the mentally retarded.
  341. The shield intrauterine device: a superior modern contraceptive.
  342. Should oral contraceptives be prescribed to teenagers? [Bor P-piller forskrives til tenaringer?]
  343. Should teenagers be given contraceptive pills? [Bor tonaringar fa p-piller?]
  344. Steroid Contraceptives.
  345. Stroke, sickle cell trait, and oral contraceptives.
  346. Studies on peripheral mechanism of action and compatibility with the parenteral contraceptive Dep-Clinovir, Depo-Provera. [Untersuchungen uber die peripheren Wirkungsmechanismen und Vertraglichkeit beim parenteralen Antikonzipiens Depo-Clinovir, Depo-Provera.]
  347. Studies on the site of action of oral contraceptive steroids. II Plasma LH and FSH levels after administration of antifertility steroids and LH-releasing hormone (LH-RH)
  348. Study Group on Health Education in Health Aspects of Family Planning, Geneva, 15-21 December 1970. Background notes.
  349. Study of family planning contraceptive boxes supplied to depot holders.
  350. Study of family planning with IUDs in a rural area) [Estudio sobre planificacion familiar con dispositivas intrauterinos en un area rural.]
  351. A study of knowledge, attitude and practice of contraception in Tonga, 1970.
  352. A study of knowledge, attitudes and practice of family planning among Uganda women: a preliminary report.
  353. Study of medroxyprogesterone: a long-acting injectable female contraceptive agent.
  354. Study of registered ayurvedic practitioners in five M.O.H. divisions in the Kandy District, on their role in maternal and child care and family planning.
  355. A study of the endometrium in intrauterine contraceptive device users.
  356. Study on the acceptability and effectiveness of an oral contraceptive among IUD drop-outs in rural Korea.
  357. Subjective efficacy and ideal family size as predictors of favorability toward birth control.
  358. Suggestions on adding family planning to the curriculums of medical schools.
  359. Summary of the conference. (Family Planning)
  360. Supression of oestradiol secretion and luteinizing-hormone release during oestrogen-progestagen oral contraceptive therapy.
  361. Surgical aspect of family planning in women.
  362. Survey on contraception. [Un'inchiesta sulla contraccezione.]
  363. Survey on induced abortion and use of contraceptives in Bogota - Method of approach. [Encuesta sobre aborto provocado y uso de anticonceptivos en Bogota - Enfoque metodologico.]
  364. Survey report: Guatemala: a survey of communications, information and education programs in family planning.
  365. Target systems in family planning: implications for program planning, evaluation, and administrative control of personnel.
  366. Targets for family planning programs.
  367. Targets in India's family planning program.
  368. A technique for projection of family planning targets and quotas required to attain demographic objectives.
  369. Teenagers in a family planning clinic.
  370. A ten-year analysis of cases visiting family planning clinics. (India)
  371. Tenth survey - 1969: Will there be a change? "Demographic revolution" and 20 years of family planning.
  372. Testimony of Dr. J.W. Goldzieher (on oral contraceptives)
  373. Theoretical basis for hormonal contraception. [Theoretische Grundlagen der hormonalen Kontrazeption.]
  374. Therapeutic considerations of the side effects of hormonal contraceptives on the liver. [Therapeutische Betrachtungen uber die Nebenwirkungen der hormonellen Anticonceptiva auf die leber.]
  375. Thin layer chromatographic separation of oral contraceptives and some sex steroids. [Dunnschichtchromatographische Trennung oraler Kontrazeptiva neben einigen Sexualsteroiden.]
  376. Thin-layer chromatographic identification of estrogens and progestogens in oral contraceptives.
  377. Third survey - 1955: diffusion of contraception.
  378. Thromboembolic disease and the steroidal content of oral contraceptives.
  379. Thromboembolic disease and the steroidal content of oral contraceptives: A report to the Committee on Safety of Drugs.
  380. Thromboembolism and oral contraception.
  381. Thromboembolism, oral contraceptives, and cigarettes.
  382. Thromboembolism, oral contraceptives, and cigarettes.
  383. Thrombosis and the content of estrogen in oral contraceptives. [Orale antikonsepsjonmidlers ostrogeninhold og trombose.]
  384. Thrombosis of a Blalock's anastomosis for Fallot's tetralogy during intake of oral contraceptives. [Thrombose d'une anastomose de Blalock pour tetralogie de Fallot, au cours d'un traitement contraceptif par un steroide anovulatoire.]
  385. Tissue deposit of progestogens and possible correlation to contraceptive activity.
  386. To teach or not to teach family planning in Kenyan primary schools.
  387. Toward a framework for the selection of family planning program evaluation topics, priorities and measures.
  388. Traditional contraceptive methods. [Die "traditionellen" Kontrazeptivmethoden.]
  389. Training field workers for family planning.
  390. Trends in contraception.
  391. Trial of a new low-dosage antiovulatory contraceptive. [Experimentation dun nouvel antiovulatoire a faible dosage.]
  392. A trial of a one dose a month oral contraceptive.
  393. The trial with oral contraceptives in Calcutta Medical College Hospital.
  394. Trichomonas vaginalis infection: incidence with use of various contraceptive methods.
  395. Tubal pregnancy and oral contraceptive taken continuously. [Grossesse tubaire et contraceptif oral en prise continue.]
  396. Turkey's Family Planning Programme.
  397. Turkey: changes in birth control practices, 1963 to 1968.
  398. Two cases of coralloid renal stones developing in young women under prolonged treatment with contraceptive pills. [Deux cas de lithiase renale coralliforme developpee chez des jeunes femmes sous traitemnt prolonge par pilule anti-conceptionelle.]
  399. Two-phase therapy (sequentials) as a method of hormonal contraception in comparison with combined preparations. [Die zweiphasentherapie als Methode der hormonalen Kontrazapation im Vergleich zu Kombinationspreparaten.]
  400. U.S. population growth and family planning: a review of the literature.
  401. U.S.S.R.: views on population/family planning.

     

  402. The ultrastructure of liver cells in women under steroid therapy: 2. Contraceptive therapy.
  403. Undesirable effects of contraceptives: 1. Introduction. [Efectos indeseables de los anticonceptivos: 1. Introduccion.]
  404. United States: knowledge, attitude, and practice of contraception among low-income women in Hawaii, 1968.
  405. United States: utilization of a family planning program in a metropolitan area.
  406. (Untitled speech on oral contraceptives.)
  407. Ureteral dilatation and oral contraceptives.
  408. Urinary catecholamine excretion and basal body temperature alterations with oral contraceptives.
  409. Urinary tract dilatation and oral contraceptives.
  410. The use of client characteristics as predictors of utilization of family planning service.
  411. The use of continuous progestogen contraception in the treatment of migraine.
  412. The use of contraceptives in Sweden.
  413. Use of microdoses of a new progestogen (Quingestanol) as a contraceptive. [Empleo de micro-dosis de un nuevo progestageno--Quingestanol--con fines anticonceptivos.]
  414. Use of oral contraceptives: a decade of controversy.
  415. Use of quingestanol acetate as a contraceptive in the puerperium (Abstract only) [Empleo del acetato de quingestanal como contraceptive enel puerperio.]
  416. The use of radio in family planning education.
  417. Use of steroidal contraception justified.
  418. Use-effectiveness of oral contraceptives by demographic characteristics.
  419. Users and non-users of contraception: tests of stationarity applied to members of a family planning programme.
  420. Using TV to recruit family planning patients.
  421. Uterine bleeding in rhesus monkeys after intrauterine contraceptive device insertion: effect of adrenosem salicylate p-aminomethylbenzoic acid.
  422. Uterine perforation caused by the use of IUDs as contraceptives. [Perforacion uterina por el uso de intrauterinos como anticonceptivos.]
  423. Uterotrophic action of an intrauterine contraceptive device in rhesus monkeys.
  424. Utilization of a family planning program by the poor population of a metropolitan area.
  425. The utilization of various types of health personnel (doctor, nurse, midwife, and auxiliaries) in the management of people using different birth control methods in hospitals, clinics, health station, home settings.
  426. Vaginal cytology in a study of cumulative effects of an oral contraceptive: acid mucopolysaccharide and keratin as indicators for cycle stages.
  427. Vaginal smear patterns in women taking ethynodiol diacetate as an oral contraceptive.
  428. Valedictory address. (Family planning seminar)
  429. Values and beliefs: approach to transnational family planning.
  430. Variations in the renin-angiotensin-aldosterone system and in antidiuretic hormone induced within 5 days by a contraceptive drug. Rapid effect of a contraceptive on the hormones controlling the metabolism of water and of sodium. [Varitions du systeme renine-angiotensine-aldosterone et de l'hormone antidiuretique induites en cinq jours par un contraceptif. Action rapide d'un contraceptif sur les hormones controlant le metabolsime de l'eau et du sodium.]
  431. Vascular lesions in women taking oral contraceptives.
  432. Visual loss associated with oral contraceptives.
  433. Vital statistics and census tract data used to evaluate family planning.
  434. The voluntary organisation in a national family planning programme.
  435. Voluntary Sterilization as a family planning measure) [Die freiwillige Sterilisation als Mittel der Familien-planung.]
  436. Warnings on oral contraceptives bring requests for IUD insertion.
  437. Wayne County post-partum family-planning program.
  438. West Malaysia: 1969 family planning acceptor follow-up survey, some preliminary findings.
  439. What is a contraceptive culture?
  440. When did they begin to practice contraception?
  441. When is the earliest postpartum contraception possible? [Wann ist eine Konzeption postpartum fruhestens moglich?]
  442. When to discontinue oral contraceptives.
  443. Women in the family planning program.
  444. Acceptability of long-term contraceptive steroid administration in humans by subcutaneous silastic capsules.
  445. Adrenocortical function related to use of oral contraceptives.
  446. The association of mortality from thromboembolic disorders and oral contraceptive use.
  447. Calcium metabolism and bone structure related to oral contraceptives.
  448. Contraceptive acceptance and pregnancy: a matrix approach to the analysis of competing risks.
  449. Contraceptive and endometrial effects of medroxyprogesterone acetate.
  450. The demographic effects of a contraceptive programme.
  451. The diagnosis of hypercortisolism: biochemical criteria differentiating patients from lean and obese normal subjects and from females on oral contraceptives.
  452. East Pakistan: fertility and family planning in Comilla.
  453. Family planning clinics in Sheffield.
  454. The goals of family planning programs in the United States.
  455. Liver function and oral contraceptives.
  456. Mortality with contraception and induced abortion.
  457. Thromboembolism and oral contraceptives: an epidemiologic case control study.
  458. Tubal pregnancy with an intrauterine contraceptive device - IUCD. [Tabargraviditat by Intrauterinpessare - JUCD.]
  459. Family planning communication research in India: main findings, programme implications and future research needs.
  460. Family planning communications in Nigeria: consulting report.
  461. Family planning exhibition.
  462. Family planning facilities in the Bombay-Thana industrial complex. (A survey)
  463. Family planning for the unmarried.
  464. Family planning in 1968: basic human right.
  465. Family planning in Argentina.
  466. Family planning in Baltimore city -- 1960-1966.
  467. Family planning in Bangkhen, Thailand.
  468. Family planning in El Salvador.
  469. Family planning in Europe. [Familjeplanering i Europa.]
  470. Family planning in hospitals.
  471. Family planning in Malaysia.
  472. Family Planning in Malaysia.
  473. Family planning in Melbourne: medical-social project.
  474. Family planning in Nigeria.
  475. Family planning in Pakistan.
  476. Family planning in the Philippines: basic problem, attitudes and programs.
  477. Family planning in Turkey: observations and an interpretative scheme.
  478. Family planning interpretation -- the nurse's role.
  479. Family planning mobile units in Turkish Population Planning Programme.
  480. Family planning on water.
  481. Family planning policies and programs development in East Africa: political and administrative aspects.
  482. The family planning program for all of Taiwan.
  483. Hepatic function during prolonged contraception. [Lo studio della funzionalita epatica nella contraccezione prolungata.]
  484. Histologic and biochemical studies of amenorrhea following oral contraception.
  485. Histological changes in the breast after the use of oral contraceptives. (Abstract only)
  486. Histological changes in the ovary under the effect of oral contraceptive.
  487. Histological study of the endometrium of 459 intrauterine contraceptive device (IUD) users.
  488. History and current status of implant contraception.
  489. History of contraception and introduction of intra-uterine contraceptive devices in a rural area--Bandaragama, Ceylon.
  490. History of family planning in Japan; from the Meiji, Taisho to the early Showa era.
  491. Honduras (Family planning)
  492. Hong Kong (Family planning)
  493. Hormonal contraception: mode of operation and methods of practice. [Hormonell antikonsepsjon. Virkingsmechanisme og anvendelse.]
  494. Hospital records - a tool to strengthen family planning in under-graduate curriculum. Appendix 6.
  495. How the program affected fertility and the practice of birth control.
  496. How to succeed in family planning.
  497. The Hungarian fertility and family planning study.
  498. Hypertension induced by oral contraceptives containing estrogen and gestagen: effects on plasma renin activity and aldosterone excretion.
  499. Ideas on a decision-information system for family planning.
  500. Immediate postpartum use of sequential oral contraceptive therapy.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.